Currently in the US and Europe, routine vaccination of infants with polysaccharide conjugate vaccines against S pneumoniae and H influenzae type b has eliminated (> 99%) H influenzae type b infections and substantially reduced (≥ 70% overall and ≥ 90% vaccine-type) invasive S pneumoniae infections.